Market Place
Sourcing Support
Nasus Pharma`s Nasal Epinephrine Powder Shows 5-Year Stability
06 Aug 2024 //
PR NEWSWIRE
Nasus Announces Positive Clinical Results of Recent Phase 2 Study With FMXIN002
05 Dec 2023 //
PR NEWSWIRE
Nasus Pharma Announces Publication Of Positive Clinical Results With FMXIN002
08 Aug 2023 //
PR NEWSWIRE
Nasus Pharma Announces Clinical Data Demonstrating Efficacy of Taffix
24 Nov 2021 //
PRNEWSWIRE
Taffix® regains marketing approval in Spain
17 Aug 2021 //
PRNEWSWIRE
Taffix® regains marketing approval in Spain
16 Aug 2021 //
PR NEWSWIRE
Taffix® blocks Delta Variant of SARS-CoV-2
19 Jul 2021 //
PR NEWSWIRE
Taffix® blocks the Delta Variant of SARS-CoV-2 in addition to the Alpha (UK)
19 Jul 2021 //
PR NEWSWIRE
Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002
23 Jun 2021 //
PRNEWSWIRE
Nasus Pharma Announces Data Demonstrating In Vitro Efficacy of Taffix®
21 Apr 2021 //
PRNEWSWIRE
Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix™
14 Oct 2020 //
PRNEWSWIRE
Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix™
13 Oct 2020 //
PRNEWSWIRE
Nasus Pharma Announces First Clinical Data Demonstrating Efficacy of Taffix™
12 Oct 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.